Now that one of Affy’s patents has been revoked — however temporarily — in Europe, companies like CombiMatrix and Applera may see the EPO as a more attractive route for opposing patents, rather than taking up the matter in the litigation-friendly US.

According to CombiMatrix’ CEO Amit Kumar, his firm has no plans to oppose any of Affymetrix’ US patents, unless the US moves to a system similar to one used in Europe and Japan that incorporates opposition into the format of granting patents.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.